Antibody Drug Conjugates: Diamonds in the Rough? – ILCN.org (ILCN/WCLC)
Drs. Matthew Lee, Benjamin Levy, and Balazs Halmos say several key issues need to be addressed before this class of agents can achieve wider impact.
Drs. Matthew Lee, Benjamin Levy, and Balazs Halmos say several key issues need to be addressed before this class of agents can achieve wider impact.
First-line treatment with the combination of Versamune HPV and pembrolizumab met a best overall response end point in recurrent/metastatic HNSCC.
ESMO is Europe’s leading medical oncology society, providing a professional network for its members and working with national societies across Europe.
Mohamad Mohty, MD, PhD, highlights key takeaways from the 50th Annual EMBT Meeting, focusing on ongoing efforts within the GVHD treatment arena.
David J. Andorsky, MD, discussed real-world findings from a study which evaluated BTK inhibitors in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
A Roswell Park-led team uncovers beneficial effects of combining VEGFR-targeting TKIs with checkpoint inhibitors in new research.
There has been several developments in the KRAS inhibitor space, shaping the KRAS inhibitors of the future.
The SGO BRIDGES Research Initiative is a new, longitudinal clinical trials workshop for early career investigators with the aim of developing the next generation of…
An abstract is unavailable.
Cancer-associated fibroblasts (CAFs) exhibit spatial and functional diversity. Here, Niu et al. unveil SETD2’s function in lipid metabolism and CAF heterogeneity in pancreatic ductal adenocarcinoma. SETD2…
Anne Chiang, MD, PhD, discusses understanding the heterogeneity of SCLC to determine which patients will respond to targeted therapy.